A seismic shift is occurring in how physicians calculate the value of cancer care. For decades, the merits of a given intervention were often measured primarily using overall survival gains, with even a few months of arrested cancer progression lauded as a major advance. Although some trials still tout such gains as the gold standard, researchers and policy makers are increasingly looking to expand the list of variables—many of them focused on quality of life and other functional outcomes—that need to be included when measuring the true value of cancer treatment.
Explore this issue:November 2015
ENTtoday spoke with head and neck surgeons and other experts who are at the forefront of such efforts. Whether it’s a groundbreaking switch away from fee-for-service medicine to a bundled care model aimed at reducing waste while maintaining quality, or healthcare policy statements encouraging physicians to emphasize quality of life and other patient-focused, longer-term endpoints, the physicians behind these initiatives are changing the national dialogue about how we should define—and deliver—value for patients who have a wide variety of malignancies.
The timing of such efforts is not accidental. Recent projections of the cost of cancer care in the United States are staggering. By the year 2020, it is estimated that cancer treatments will cost more than $200 billion annually, according to data from the National Cancer Institute, with head and neck cancers expected to account for nearly $2 billion of that projected spending.